

"A global leader in cancer screening, detection, and treatment guidance through genomic testing"
Exact Sciences develops cancer diagnostic tests that detect cancer earlier and guide personalised treatment. Its portfolio includes Cologuard, a noninvasive colorectal cancer screening test, Cancerguard, a multi-cancer blood test, and Oncotype DX genomic tests for treatment decisions. These tests combine DNA analysis, biomarker detection, and genomic profiling to provide actionable insights. The company serves patients, providers, and oncologists across 120 countries. By partnering with research institutions and advocacy groups, Exact Sciences advances early cancer detection and therapy selection, addressing a critical gap where earlier diagnosis and personalised treatment improve survival rates and quality of life.


7200
Team Members
1995
Founded
Diagnostics
Sector
Hybrid
Work Environment
A world where cancer is prevented, detected at its earliest and most treatable stages, and managed with precision through personalised genomic insights that improve survival and quality of life for every patient.
At Exact Sciences, our mission is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalised treatment.